ReviewEndocrine, metabolic & immune disorders drug targets2026
Intervention Strategies using
Review in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChemicals consumed through food, water, air, and personal care products disrupt our endocrine system, contributing to a range of life-threatening diseases. Since this toxicity is cumulative, it is essential to incorporate the principles of toxicity treatment. The review was conducted to evaluate the potential utility of Agada formulations in managing diseases associated with endocrine-disrupting chemicals.
methodsElectronic searches were performed using terms "Agada", "Ayurveda", "antitoxic", "visha", "dūṣhivīṣha", "endocrine-disrupting chemicals", and "toxicity" including animal, clinical, or pharmacological studies of Agada formulations in any toxicant or cumulative toxin model; or conceptual reviews linking Agada to environmental/chemical toxicity. By reviewing Ayurvedic literature, studying research on
resultsThe conceptual framework of DISCUSSION: Agada formulations may offer an integrative approach to mitigating EDC-related diseases. Their known pharmacological actions, such as antioxidant activity, free radical scavenging, Nrf2 upregulation, NF-κB inhibition, and adaptogenic effects, align with the major pathophysiological pathways triggered by EDCs. However, the current evidence base is limited by the absence of standardized formulations, inconsistent dosing, lack of endocrine biomarker assessment, and a scarcity of clinical trials.
conclusionBy applying the treatment principles of Garavisha (swallowed poison) and Dushivisha (latent poison), disorders resulting from endocrine disruptors can be effectively addressed using Agada directing to generate empirical evidences through clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.